Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280573 | 0.86 | MAPT (0.41) | JAK2MAPTLMNAPKMRAB9A | |
| SCHEMBL4286269 | 0.79 | ALDH1A1 (0.45) | MAPTLMNARAB9AALDH1A1ABCG2 | |
| SCHEMBL4292919 | 0.75 | ALDH1A1 (0.47) | MAPTLMNAPKMRAB9AALDH1A1 | |
| SCHEMBL11453175 | 0.73 | LMNA (0.57) | MAPTLMNAALDH1A1ABCG2HPGD | |
| SCHEMBL23422083 | 0.71 | ALDH1A1 (0.42) | MAPTLMNARAB9AALDH1A1ABCG2 | |
| SCHEMBL29715554 | 0.71 | ALDH1A1 (0.42) | MAPTLMNARAB9AALDH1A1ABCG2 | |
| SCHEMBL7706101 | 0.71 | HTT (0.58) | MAPTLMNAALDH1A1HPGDMEN1 | |
| SCHEMBL23293751 | 0.71 | ALDH1A1 (0.48) | MAPTLMNAALDH1A1ABCG2MEN1 | |
| SCHEMBL10596737 | 0.70 | MEN1 (0.56) | MAPTLMNAALDH1A1ABCG2HPGD | |
| SCHEMBL4203388 | 0.70 | TSHR (0.67) | MAPTLMNAALDH1A1ABCG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, TYK2, LTK | JAK2 40/4885MAPT 1810/4885LMNA 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.